Ali Hassanzadeh

Dr. Ali Hassanzadeh

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SNSepehr Nayebirad
Sepehr Nayebirad
AHAli Hassanzadeh
Ali Hassanzadeh
AVAmir Mohammad Vahdani
Amir Mohammad Vahdani
AMAida Mohamadi
Aida Mohamadi
SFShayan Forghani
Shayan Forghani
FMFarzad Masoudkabir
Farzad Masoudkabir
Percutaneous coronary intervention (PCI) has been the main treatment of coronary artery disease (CAD). In this review, we aimed to compare the performance of machine learning (ML) vs. logistic regression (LR) models in predicting different outcomes after PCI. Studies using ML or deep learning (DL) models to predict mortality, MACE, in-hospital bleeding, and acute kidney injury (AKI) after PCI or primary PCI were included. Articles were excluded if they did not provide a c-statistic, solely used ML models for feature selection, were not in English, or only used logistic or LASSO regression models. Best-performing ML and LR-based models (LR model or conventional risk score) from the same studies were pooled separately to directly compare the performance of ML versus LR. Risk of bias was assessed using the PROBAST and CHARMS checklists. A total of 59 studies were included. Meta-analysis showed that ML models resulted in a higher c-statistic compared to LR in long-term mortality (0.84 vs. 0.79, P-value = 0.178), short-term mortality (0.91 vs. 0.85, P = 0.149), bleeding (0.81 vs. 0.77 P = 0.261), acute kidney injury (AKI; 0.81 vs. 0.75, P = 0.373), and major adverse cardiac events (MACE; 0.85 vs. 0.75, P = 0.406). PROBAST analysis showed that 93% of long-term mortality, 70% of short-term mortality, 89% of bleeding, 69% of AKI, and 86% of MACE studies had a high risk of bias. No statistical significance existed between ML and LR model. In addition, the high risk of bias in ML studies and complexity in interpretation undermines their validity and may impact their adaption in a clinical settings.

12 April 2024 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
AJArash Jalali
Arash Jalali
AHAli Hassanzadeh
Ali Hassanzadeh
MNMohammad Sadeq Najafi
Mohammad Sadeq Najafi
SNSepehr Nayebirad
Sepehr Nayebirad
MDMohadese Dashtkoohi
Mohadese Dashtkoohi
ASAkbar Shafiee
Akbar Shafiee
Aim: We systematically reviewed and meta-analyzed the predictors of major adverse cardiac and cerebrovascular events (MACE/MACCE) in older adults who underwent PCI. Methods: Three databases, PubMed, Embase, and Scopus, were searched for observational studies considering the out-of-hospital MACE/MACCE in adults ≥ 60 years old with coronary artery disease (acute or chronic) who underwent PCI. Studies were eligible if they had determined at least two statistically significant predictors of MACE/MACCE by multivariable analysis. We used the QUIPS tool to evaluate the risk of bias in the studies. Random-effects meta-analysis was utilized to pool the hazard ratios (HRs) of the most reported predictors. Results: A total of 34 studies were included in the review. Older age (HR = 1.04, 95% Confidence Interval (CI): 1.03–1.06, P-value < 0.001), diabetes (HR = 1.36, 95% CI: 1.22–1.53, P < 0.001), history of myocardial infarction (MI) (HR = 1.88, 95% CI: 1.37–2.57, P < 0.001), ST-elevation MI (STEMI) at presentation (HR = 1.72, 95% CI: 1.37–2.18, P < 0.001), reduced left ventricular ejection fraction (LVEF) (HR = 2.01, 95% CI: 1.52–2.65, P < 0.001), successful PCI (HR = 0.35, 95% CI: 0.27–0.47, P < 0.001), eGFR (HR = 0.99, 95% CI: 0.97-1.00; P-value = 0.04) and left main coronary artery (LMCA) disease (HR = 2.07, 95% CI: 1.52–2.84, P < 0.001) were identified as predictors of MACE. Conclusion: We identified older age, diabetes, history of MI, STEMI presentation, lower LVEF, and LMCA disease increased the risk of MACE/MACCE after PCI in older adults. Meanwhile, higher eGFR and successful PCI predicted lower adverse events risk. Future studies should focus on a more robust methodology and a precise definition of MACE. Registration: PROSPERO (CRD42023480332).

23 August 2024 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
MPMohammad Poursalehian
Mohammad Poursalehian
AHAli Hassanzadeh
Ali Hassanzadeh
SSSeyyed Hossein Shafiei
Seyyed Hossein Shafiei
SMSeyed Mohammad Javad Mortazavi
Seyed Mohammad Javad Mortazavi

25 March 2024 in EXCLI Journal
Verified
Journal Article
Open access
AHAli Hassanzadeh
Ali Hassanzadeh
NSNavid Shomali
Navid Shomali
MAMajid Ahmadi
Majid Ahmadi
HNHadi Nasiri
Hadi Nasiri
JHJavad Ahmadian Heris
Javad Ahmadian Heris
MAMorteza Akbari
Morteza Akbari
Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases.

4 June 2024 in EXCLI Journal
Verified
Journal Article
Open access
AHAli Hassanzadeh
Ali Hassanzadeh
NSNavid Shomali
Navid Shomali
MAMajid Ahmadi
Majid Ahmadi
MSMohammad Sadegh Soltani-Zangbar
Mohammad Sadegh Soltani-Zangbar
HNHadi Nasiri
Hadi Nasiri
MAMorteza Akbari
Morteza Akbari
A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.

24 April 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAli Hassanzadeh
Ali Hassanzadeh
MHMalihe Hasannezhad
Malihe Hasannezhad
LALadan Abbasian
Ladan Abbasian
SGSara Ghaderkhani
Sara Ghaderkhani
FAFereshteh Ameli
Fereshteh Ameli
MAMehdi Allahdadi
Mehdi Allahdadi
Background: Immunodeficient patients, particularly HIV patients, are at risk of opportunistic infections. Nontuberculous mycobacteria can cause severe complications in immunodeficient patients. Case Presentation: We describe a 57-year-old HIV patient, primarily presented with coughs and constitutional symptoms, with a unique Mycobacterium genavense abdominal, pulmonary, and central nervous system infection, accompanied by intracranial masses. Conclusion: The diagnosis of NTM, including M. genavense, must always be considered by clinicians in immunodeficient patients, especially those with HIV, who have a compromised immune system.